A Prospective, Multicenter, Open-label, Single-arm Study to Assess the Tolerability, Safety and Efficacy of a New Frequency of Vibrant Capsule Administration
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- Vibrant Ltd.
- 入组人数
- 25
- 试验地点
- 4
- 主要终点
- Spontaneous Bowel Movements Success Rate
研究概览
简要总结
The study is a prospective, multicenter, open-label, single-arm study, to evaluate the tolerability, safety and efficacy of the Vibrant Capsule in relieving constipation.
详细描述
One arm will be assessed: Vibrant Capsule administered with a sequence of one per day for 2 days, followed by one day without, one per day for 2 days followed by one day without, etc. (14 capsules in 3 weeks).
The study will have one interim analysis.
Patients will follow a 2 weeks baseline period and then take the Vibrant Capsule for a treatment period of 6 weeks.
Data reporting will be done on an electronic Case Report Form and an eDiary. During the 2 weeks of baseline, patients will be asked to refrain from taking any medication or supplement to relieve their constipation.
After 14 days the patients will return and eligibility will be re-assessed. Patients will be trained on how to use the base unit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 22 years and older
- •Patients with Chronic Idiopathic Constipation according to Rome III criteria and who have not experienced relief of their symptoms from available therapies (osmotic and stimulant laxatives used for at least one month at recommended dose)
- •Patients with an average of less than 3 Spontaneous Bowel Movements per week and at least 1 Spontaneous Bowel Movements per week
- •Normal colonoscopy performed within 10 years prior to study participation, unless the patients are less than 50 years old and without alarm signs and/or symptoms
- •Patient signed the Informed Consent Form
- •Female subjects must have a negative urine pregnancy test and must not be lactating prior to receiving study medication. For females of child-bearing potential, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. All other female subjects must have the reason for their inability to bear children documented in the medical record; in these circumstances, a urine pregnancy test will not be necessary.
排除标准
- •History of complicated/obstructive diverticular disease
- •History of intestinal or colonic obstruction, or suspected intestinal obstruction.
- •History of significant gastrointestinal disorder, including any form of inflammatory bowel disease or gastrointestinal malignancy (celiac disease is accepted if the subject has been treated and is in remission)
- •History of gastroparesis
- •Use of any of the following medications:
- •Medications that may affect intestinal motility, prokinetics, anti-depressants, anti-Parkinsonian medications, opiates, opioids, calcium-channel blockers, aluminum/magnesium hydroxide
- •With the exception of antidepressants, thyroid or hormonal replacement therapy, when the subject has been on a stable dose for at least 3 months prior to enrollment.
- •Clinical evidence of significant respiratory, cardiovascular, renal, hepatic, biliary, endocrine, psychiatric or neurologic disease.
- •Presence of cardiac pacemaker or gastric electrical stimulator.
- •History of, or current eating disorders, such as anorexia, bulimia, or compulsory overeating.
- •Diagnosis of mega-rectum or colon, congenital anorectal malformation, clinically significant rectocele, history of intestinal resection (with an exception for appendectomy, cholecystectomy and inguinal hernia repair), history of bariatric surgery or evidence of any structural abnormality of the gastrointestinal tract that might affect transit
- •History of Zenker's diverticulum, dysphagia, Barrett's esophagus, esophageal stricture or achalasia
- •Chronic use of non-steroidal anti-inflammatory drugs: chronic use is defined as taking full dose non-steroidal anti-inflammatory drugs more than three times a week for at least six months. Patients on cardiac doses of aspirin may be enrolled in the study
- •Patients with pelvic floor dysfunction/defecatory disorder, based on patient history
- •Participation in another clinical study within one month prior to screening.
- •Women who are pregnant or lactating
- •Use of any medication for constipation relief during the study, except as rescue medication, as indicated by study rules
- •Inability to use an electronic daily Diary (on a computer, phone application, tablet or other electronic device) to report bowel movements, symptoms and medication usage
- •Any other condition which in the opinion of the investigator may adversely affect the safety of the patient or would limit the patient's ability to complete the study
研究组 & 干预措施
Vibrating Capsule
Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
干预措施: Vibrating Capsule (Device)
结局指标
主要结局
Spontaneous Bowel Movements Success Rate
时间窗: 6 weeks of treatment
Defined as the number of subjects with an increase from the run-in period of at least one weekly Spontaneous Bowel Movement (SBM) during at least 3 of the 6 weeks of treatment. Subjects with less than 2 weeks (with at least 5 days per week) of valid diary during the treatment period will be considered as non-evaluable.
次要结局
未报告次要终点